197 related articles for article (PubMed ID: 25363737)
1. Novel Nrf2 activators from microbial transformation products inhibit blood-retinal barrier permeability in rabbits.
Nakagami Y; Masuda K; Hatano E; Inoue T; Matsuyama T; Iizuka M; Ono Y; Ohnuki T; Murakami Y; Iwasaki M; Yoshida K; Kasuya Y; Komoriya S
Br J Pharmacol; 2015 Mar; 172(5):1237-49. PubMed ID: 25363737
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability.
Nakamura S; Noguchi T; Inoue Y; Sakurai S; Nishinaka A; Hida Y; Masuda T; Nakagami Y; Horai N; Tsusaki H; Hara H; Shimazawa M
Invest Ophthalmol Vis Sci; 2019 May; 60(6):1943-1952. PubMed ID: 31050722
[TBL] [Abstract][Full Text] [Related]
3. A novel nuclear factor erythroid 2-related factor 2 (Nrf2) activator RS9 attenuates brain injury after ischemia reperfusion in mice.
Yamauchi K; Nakano Y; Imai T; Takagi T; Tsuruma K; Shimazawa M; Iwama T; Hara H
Neuroscience; 2016 Oct; 333():302-10. PubMed ID: 27474227
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases.
Nakagami Y
Oxid Med Cell Longev; 2016; 2016():7469326. PubMed ID: 27818722
[TBL] [Abstract][Full Text] [Related]
5. A novel Nrf2 activator from microbial transformation inhibits radiation-induced dermatitis in mice.
Nakagami Y; Masuda K
J Radiat Res; 2016 Sep; 57(5):567-571. PubMed ID: 27242339
[TBL] [Abstract][Full Text] [Related]
6. Cytoprotective Effects of a Novel Nrf2 Activator, RS9, in Rhodopsin Pro347Leu Rabbits.
Nakagami Y; Hatano E; Inoue T; Yoshida K; Kondo M; Terasaki H
Curr Eye Res; 2016 Aug; 41(8):1123-1126. PubMed ID: 26430824
[TBL] [Abstract][Full Text] [Related]
7. RS9, a novel Nrf2 activator, attenuates light-induced death of cells of photoreceptor cells and Müller glia cells.
Inoue Y; Shimazawa M; Noda Y; Nagano R; Otsuka T; Kuse Y; Nakano Y; Tsuruma K; Nakagami Y; Hara H
J Neurochem; 2017 Jun; 141(5):750-765. PubMed ID: 28345128
[TBL] [Abstract][Full Text] [Related]
8. A triterpenoid Nrf2 activator, RS9, promotes LC3-associated phagocytosis of photoreceptor outer segments in a p62-independent manner.
Saito Y; Yako T; Otsu W; Nakamura S; Inoue Y; Muramatsu A; Nakagami Y; Shimazawa M; Hara H
Free Radic Biol Med; 2020 May; 152():235-247. PubMed ID: 32217192
[TBL] [Abstract][Full Text] [Related]
9. NFE2L2 activator RS9 protects against corneal epithelial cell damage in dry eye models.
Matsuda Y; Machida M; Nakagami Y; Nakajima T; Azuma M
PLoS One; 2020; 15(4):e0229421. PubMed ID: 32320433
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy.
Deliyanti D; Alrashdi SF; Tan SM; Meyer C; Ward KW; de Haan JB; Wilkinson-Berka JL
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):815-825. PubMed ID: 29411009
[TBL] [Abstract][Full Text] [Related]
11. Bardoxolone methyl decreases megalin and activates nrf2 in the kidney.
Reisman SA; Chertow GM; Hebbar S; Vaziri ND; Ward KW; Meyer CJ
J Am Soc Nephrol; 2012 Oct; 23(10):1663-73. PubMed ID: 22859857
[TBL] [Abstract][Full Text] [Related]
12. A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy.
Deliyanti D; Lee JY; Petratos S; Meyer CJ; Ward KW; Wilkinson-Berka JL; de Haan JB
Clin Sci (Lond); 2016 Aug; 130(15):1375-87. PubMed ID: 27005782
[TBL] [Abstract][Full Text] [Related]
13. Bardoxolone Methyl Displays Detrimental Effects on Endothelial Bioenergetics, Suppresses Endothelial ET-1 Release, and Increases Endothelial Permeability in Human Microvascular Endothelium.
Szczesny-Malysiak E; Stojak M; Campagna R; Grosicki M; Jamrozik M; Kaczara P; Chlopicki S
Oxid Med Cell Longev; 2020; 2020():4678252. PubMed ID: 33123312
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure.
Tian C; Gao L; Zhang A; Hackfort BT; Zucker IH
J Pharmacol Exp Ther; 2019 Dec; 371(3):642-651. PubMed ID: 31601682
[TBL] [Abstract][Full Text] [Related]
15. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway.
Wu J; Liu X; Fan J; Chen W; Wang J; Zeng Y; Feng X; Yu X; Yang X
Toxicology; 2014 Apr; 318():22-31. PubMed ID: 24530882
[TBL] [Abstract][Full Text] [Related]
16. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells.
Huang K; Huang J; Xie X; Wang S; Chen C; Shen X; Liu P; Huang H
Free Radic Biol Med; 2013 Dec; 65():528-540. PubMed ID: 23891678
[TBL] [Abstract][Full Text] [Related]
17. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure.
Kim HJ; Vaziri ND
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F662-71. PubMed ID: 20007347
[TBL] [Abstract][Full Text] [Related]
18. Betulinic acid, isolated from the leaves of Syzygium cumini (L.) Skeels, ameliorates the proteinuria in experimental membranous nephropathy through regulating Nrf2/NF-κB pathways.
Sutariya B; Taneja N; Saraf M
Chem Biol Interact; 2017 Aug; 274():124-137. PubMed ID: 28711658
[TBL] [Abstract][Full Text] [Related]
19. Bardoxolone ameliorates TGF-β1-associated renal fibrosis through Nrf2/Smad7 elevation.
Song MK; Lee JH; Ryoo IG; Lee SH; Ku SK; Kwak MK
Free Radic Biol Med; 2019 Jul; 138():33-42. PubMed ID: 31059771
[TBL] [Abstract][Full Text] [Related]
20. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
